In plain words
In one six-week trial, people with mild to moderate depression who took a rhodiola extract improved on a depression scale, while those on a placebo did not. The trials that lasted 28 days and 12 weeks found no significant difference between rhodiola and placebo. In one of them, both groups improved.
The short answer
Two of the three randomized trials found no significant difference from placebo. In Mao and colleagues' (2015) 12-week trial in mild to moderate major depression, rhodiola lowered the HAM-D score 0.5 points more than placebo; the ledger has no n or dose for it. In Olsson and colleagues' (2008) trial of 576 mg a day for 28 days in 60 people, depression scores improved in both groups. The third, by Darbinyan and colleagues (2007), found depression improved at 340 or 680 mg a day over six weeks in 89 people, while the placebo group did not. Certainty is low because the trials are few and short and point different ways.
Where the evidence sits
Depression improved vs placebo
No difference from placebo
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Mao et al., 2015 | No significant difference between groups | Randomized; placebo and sertraline arms | Mild to moderate major depression; n not in ledger | 12 weeks; dose not in ledger | Not in ledger |
| Olsson et al., 2008 | Both groups improved | Randomized, placebo-controlled | 60 | 576 mg a day for 28 days | Not in ledger |
| Darbinyan et al., 2007 | Both doses improved; placebo did not | Randomized, placebo-controlled | 89, mild to moderate depression | 340 or 680 mg a day, 6 weeks | Not in ledger |
| EBSCO Research Starters | Both doses improved; placebo did not | Reference publisher describing a randomized trial | 89, as described | As described: 340 or 680 mg, 6 weeks | Not in ledger |
No significant difference between groups
Both groups improved
Both doses improved; placebo did not
Both doses improved; placebo did not
What did the 12-week trial against sertraline find?
Mao and colleagues (2015) compared rhodiola with the antidepressant sertraline and with placebo over 12 weeks in people with mild to moderate major depressive disorder; the ledger has no n or dose for this trial. They reported:
Modest, albeit statistically non-significant, reductions were observed for HAM-D, BDI, and CGI/C scores for all treatment conditions with no significant difference between groups
At week 12, rhodiola lowered the 17-item HAM-D score 0.5 points more than placebo, against 3.6 points for sertraline. The authors wrote that their findings suggest rhodiola may have modest antidepressant effects in some patients, and that it caused significantly fewer adverse events than sertraline.
What happened in the 28-day trial?
Olsson and colleagues (2008) gave 60 people 576 mg of SHR-5 a day, or a placebo, for 28 days, and measured depression on the MADRS scale alongside burnout and mental health:
Significant post-treatment improvements were observed for both groups (placebo effect) in Pines' burnout scale, mental health (SF-36), and MADRS
The ledger records no significant difference between the groups on depression.
What did the six-week trial find?
Darbinyan and colleagues (2007) randomized 89 people with mild to moderate depression to 340 mg or 680 mg a day of SHR-5, or a placebo, for six weeks. Overall depression on the HAMD improved in both extract groups but not in the placebo group. The authors concluded:
It is concluded that the standardized extract SHR-5 shows anti-depressive potency in patients with mild to moderate depression when administered in dosages of either 340 or 680 mg/day over a 6-week period.
EBSCO Research Starters describes an 89-person, six-week trial of 340 mg or 680 mg that appears to be this one, so its account is the same measurement, not a second one.
Why the sources disagree
Comparison: the positive trial set rhodiola against placebo alone; the 12-week trial added sertraline, and scores fell modestly in every group. Scales differed: HAMD, 17-item HAM-D and MADRS. Population: the ledger has no diagnosis for the 2008 trial. Dose: the 2007 and 2008 trials used SHR-5 at 340 to 680 mg a day; the ledger has no dose for the 2015 trial. EBSCO repeats a trial rather than adding one. The ledger has no funding source for any trial.
What would settle it
An independent, pre-registered trial in adults with mild to moderate depression, randomizing several hundred people to one standardized rhodiola extract at a fixed daily dose, placebo, or sertraline for 12 weeks, reporting HAM-D change against placebo at 6 and 12 weeks, with funding disclosed. A matching result from a second research group would raise certainty above low.
How this page was made
The 4 sources are three randomized trials from PubMed and PubMed Central, found in a literature search on rhodiola rosea, and one reference publisher, EBSCO Research Starters, that appears to describe one of them. Claims on fatigue, energy, cognition and side effects were left out unless they bore on depression. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. "Contested" means independent trials point in both directions; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
The ledger holds only 3 studies on this question.
Changelog: 23 Sep 2026, first version, 4 sources.
